EJCTS Click here for details of sales representative
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Francesco Puma
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Daddi, N.
Right arrow Articles by Daddi, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Daddi, N.
Right arrow Articles by Daddi, G.
Related Collections
Right arrow Lung - cancer
Right arrow Trachea and bronchi

Eur J Cardiothorac Surg 2004;26:813-817
© 2004 Elsevier Science NL


Surgical treatment of neuroendocrine tumors of the lung

Niccolo' Daddia,1, Piero Ferollab,1, Moira Urbania, Antonia Semeraroa, Nicola Aveniaa, Rodolfo Ribacchic, Francesco Pumaa, Giuliano Daddia*

a Thoracic Surgery, University of Perugia, Policlinico Monteluce, Via Brunamonti 51, 06122 Perugia, Italy
b DIMISEM, University of Perugia, Perugia and Terni, Italy
c Institute of Pathology, University of Perugia, Perugia and Terni, Italy

Received 14 October 2003; received in revised form 16 April 2004; accepted 31 May 2004.

* Corresponding author. Tel.: +39-075-578-3208; fax: +39-075-578-3329
e-mail: gdaddi{at}unipg.it

Objective: This report reviews the pattern of neuroendocrine (NE) differentiation, lymph-node involvement, extension of surgery, and survival in 125 NE lung tumor patients. Methods: Standard diagnostic workup included CT scan, bronchoscopy, bronchial biopsy or Fine Needle Aspiration Biopsy, 111In-pentetreotide scan (OctreoScan) and mediastinoscopy in selected patients. NE differentiation was assessed based on the morphology and immunohistochemical reactivity for pan-neuroendocrine markers NSE, CGA, and Synaptophysin. For small cell carcinoma (SCC), only clinical stage I and II patients underwent surgery. Several different surgical procedures were utilized, from limited resections to lobectomy, pneumonectomy, and bronchoplastic procedures. Survival was assessed using Kaplan–Meyer method at 5 years. Results: There were 79 typical carcinoid (TC), eight atypical carcinoid (AC), 18 large cell carcinoma (LCC) and 20 SCC patients. Mean age at diagnosis was 54.6±15.2 (ranges from 16 to 77 years) for TC, 68.5±9.1 (range 53–81) for AC, 68.7±4.6 (range 58–77) for LCC, 64.6±7.9 (range 48–82) for SCC. Male/female ratio was 1/1 for TC and AC, 2.6/1 for LCC and 9/1 for SCC. Lymph-node involvement was present in 14% of TC, 0% of AC, 31.5% of LCC, and 45% of SCC. Cancer specific survival was 96% for TC, 87.5% for AC, 37.5% for LCC, and 30% for SCC at 5 years from surgery. Presenting symptoms were invariably of respiratory-related. None had the carcinoid syndrome. History of tobacco abuse ranged from 46% for TC to 100% in SCC. Survival ranged from a minimum of 1 month for SCC to a maximum of 168 months with no evidence of disease for TC. Synchronous multicentric forms were found in 14% of TC. Twenty-one percent (4/19) of the patients with SCC treated by induction therapy and surgery, and in few cases by surgery and adjuvant chemotherapy are alive without the evidence of the disease for 5 years. Conclusions: Due to the high percentage of lymph-node involvement and multicentric forms found in our series lobectomy with radical lymph-node dissection appears, in our opinion, the most appropriate surgical treatment in well-differentiated forms, while more limited resection appears sub-optimal. Also, due to the finding of recurrences many years after surgery, the follow-up must be accurate and protracted in this subgroup. Only Small Cell Lung Carcinoma patients in clinical stage I and II underwent surgery with good long-term results.

Key Words: Neuroendocrine tumors • Surgical treatment • Lung tumors • Carcinoids • Small cell carcinoma • Large cell carcinoma




This article has been cited by other articles:


Home page
Eur. J. Cardiothorac. Surg.Home page
J.-C. Das-Neves-Pereira, P. Bagan, J.-R. Milanez-de-Campos, V.-L. Capelozzi, C. Danel, F.-B. Jatene, J.-F. Bernaudin, and M. Riquet
Individual risk prediction of nodal and distant metastasis for patients with typical bronchial carcinoid tumors
Eur. J. Cardiothorac. Surg., September 1, 2008; 34(3): 473 - 478.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2004 European Association for Cardio-Thoracic Surgery. Published by Elsevier. All rights reserved.